4C Medical Technologies Completes $35 Million Series C Financing And Appoints Saravana Kumar As President And Ceo

Mar 31, 2022•over 3 years ago

Amount Raised

$35 Million

Round Type

series c

Minneapolis

Description

4C Medical Technologies, Inc. ("4C Medical" or the "Company"), a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, announced that it has completed a $35.4 million Series C Preferred Stock financing. The Series C round was led by MicroPort CardioFlow Medtech Corporation (HKEX:2160).

Company Information

Company

4 C Medical Technologies

Location

Minneapolis, Minnesota, United States

About

4C Medical is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. Subject to regulatory approvals, the Company's AltaValve® would be the first MR treatment with atrial-only fixation that is designed to minimize known issues associated with current TMVR technologies, which rely on placement and fixation within the native mitral annulus.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech